Jan 20 2010
Edwards Lifesciences Corporation (NYSE: EW), the
world leader in the science of heart valves, announced today that the
Federal Patent Court in Munich, Germany, has upheld the validity of
Edwards' German Andersen patent for transcatheter valve technology.
Edwards succeeded in having CoreValve's invalidity claims dismissed on all
grounds.
"We are very pleased that Edwards' Andersen patent has again been upheld,
as it was last year in the United Kingdom," said Larry L. Wood, Edwards'
corporate vice president, transcatheter valve replacement.
Today's decision resulted from a counter-suit filed by CoreValve in
response to the patent infringement case filed by Edwards in Germany in May
2007.
SOURCE: Edwards Lifesciences
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses